Vertex Pharmaceuticals (VRTX) Operating Leases (2018 - 2026)

Vertex Pharmaceuticals (VRTX) has reported Operating Leases for 9 consecutive years, with $2.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases rose 29.19% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $2.0 billion (up 29.19% YoY), while the FY2025 annual figure was $1.8 billion, up 19.56% from the prior year.
• Operating Leases came in at $2.0 billion for Q1 2026 at Vertex Pharmaceuticals, up from $1.8 billion in the prior quarter.
• The five-year high for Operating Leases was $2.0 billion in Q1 2026, with the low at $348.6 million in Q4 2023.
• Average Operating Leases over 5 years is $929.6 million, with a median of $428.1 million recorded in 2022.
• Across the five-year window, Operating Leases decreased 18.57% in 2023 and soared 348.34% in 2024, its largest moves.
• Year by year, Operating Leases stood at $428.1 million in 2022, then dropped by 18.57% to $348.6 million in 2023, then soared by 343.03% to $1.5 billion in 2024, then increased by 19.56% to $1.8 billion in 2025, then advanced by 7.58% to $2.0 billion in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $2.0 billion, $1.8 billion, and $1.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.